JY
AGRX

Jeff Yass’s Agile Therapeutics AGRX Stock Holding History

Jeff Yass’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5
Closed -$22K – 13509
2021
Q1 		$22K Hold
5
– – ﹤0.01% 12135
2020
Q4 		$29K Sell
5
-25
-83% -$147K ﹤0.01% 10849
2020
Q3 		$183K Sell
30
-28
-48% -$160K ﹤0.01% 9528
2020
Q2 		$322K Buy
58
+31
+115% +$161K ﹤0.01% 8234
2020
Q1 		$101K Sell
27
-22
-45% -$126K ﹤0.01% 9318
2019
Q4 		$246K Buy
+49
New +$171K ﹤0.01% 8394

Other funds holding AGRX

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Jeff Yass's AGRX Position: Q1 2023 in Review

Jeff Yass sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 289 shares — an estimated $3.28K sold.

Jeff Yass first reported a position in AGRX in Q4 2016 and held it in 18 quarters. The position peaked at $1.23M in Q1 2020. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Jeff Yass reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Jeff Yass sold 289 Agile Therapeutics shares in Q1 2023, an estimated $3.28K.
  • Jeff Yass first reported a position in Agile Therapeutics in Q4 2016 and held it in 18 quarters.
  • Jeff Yass's Agile Therapeutics position peaked at $1.23M in Q1 2020.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.